SCHEMBL5545477

SCHEMBL5545477

O=C(NCCCO)c1c(O)c2ncc(Cc3ccc(F)cc3)cc2n(CCCN2CCCCC2=O)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.41
GAA P10253 2/20 0.41
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 3/20 0.40
LMNA P02545 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 2/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 2/20 0.38
NAMPT P43490 1/20 0.37
LIPG Q9Y5X9 1/20 0.37
MEN1 O00255 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
CASK O14936 1/20 0.37
MERTK Q12866 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
PARP1 P09874 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546517 0.99 CYP2C19 (0.41) CYP2C19GAAKDM4EALDH1A1LMNA
SCHEMBL5547352 0.97 CYP2C19 (0.40) CYP2C19GAAKDM4EALDH1A1LMNA
SCHEMBL5545748 0.96 CYP2C19 (0.40) CYP2C19GAAKDM4EALDH1A1LMNA
SCHEMBL5545621 0.96 CYP2C19 (0.40) CYP2C19GAAKDM4EALDH1A1LMNA
SCHEMBL5547007 0.95 CYP2C19 (0.40) CYP2C19GAAKDM4EALDH1A1LMNA
SCHEMBL5545332 0.95 CYP2C19 (0.42) CYP2C19GAAKDM4EALDH1A1LMNA
SCHEMBL5539125 0.95 CYP2C19 (0.45) CYP2C19GAAKDM4EALDH1A1LMNA
SCHEMBL5538960 0.95 CYP2C19 (0.42) CYP2C19GAAKDM4EALDH1A1LMNA
SCHEMBL5539930 0.95 CYP2C19 (0.46) CYP2C19GAAKDM4EALDH1A1LMNA
SCHEMBL5541114 0.94 CYP2C19 (0.40) CYP2C19GAAKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 CYP2C19 2324/4885GAA 2514/4885KDM4E 1268/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 CYP2C19 2455/4885GAA 1077/4885KDM4E 1255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.